

Genevieve M Boland

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5995249/publications.pdf](https://exaly.com/author-pdf/5995249/publications.pdf)

Version: 2024-02-01

109
papers

11,697
citations

70409

40
h-index

33030

98
g-index

440
all docs

440
docs citations

440
times ranked

24121
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	27.7	1,370
2	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	27.7	973
3	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	13.0	724
4	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	27.7	552
5	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	14.1	532
6	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	29.9	521
7	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. <i>Immunity</i> , 2019, 50, 1498-1512.e5.	14.0	449
8	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	14.1	429
9	Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics. <i>Cell</i> , 2019, 176, 1325-1339.e22.	27.7	386
10	Spatially organized multicellular immune hubs in human colorectal cancer. <i>Cell</i> , 2021, 184, 4734-4752.e20.	27.7	338
11	The Human and Mouse Enteric Nervous System at Single-Cell Resolution. <i>Cell</i> , 2020, 182, 1606-1622.e23.	27.7	328
12	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	27.7	303
13	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	35.8	281
14	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017, 77, 2318-2327.	0.9	249
15	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	29.9	241
16	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	13.7	232
17	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	7.2	200
18	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2019, 176, 404.	27.7	197

#	ARTICLE	IF	CITATIONS
19	Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. <i>Cancer</i> , 2013, 119, 1593-1601.	4.1	187
20	Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. <i>Nature Biotechnology</i> , 2021, 39, 451-461.	20.6	180
21	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	165
22	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. <i>Cell</i> , 2021, 184, 6262-6280.e26.	27.7	158
23	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	35.8	146
24	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	139
25	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. <i>Cancer Discovery</i> , 2021, 11, 678-695.	14.1	135
26	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 1459-1470.	6.6	108
27	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1196-1205.	7.2	90
28	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti- α PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	7.2	89
29	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	35.8	86
30	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. <i>Cell Reports</i> , 2017, 21, 2796-2812.	6.3	85
31	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867.	7.2	85
32	Co-targeting β and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.8	83
33	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	13.0	77
34	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	14.1	76
35	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	29.9	72
36	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. <i>Oncotarget</i> , 2017, 8, 25395-25417.	1.9	68

#	ARTICLE	IF	CITATIONS
37	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	3.3	64
38	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	13.3	62
39	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	4.4	44
40	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020, 6, .	10.8	44
41	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. <i>JAMA Surgery</i> , 2016, 151, 347.	4.5	42
42	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015, 6, 20099-20110.	1.9	42
43	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17.	4.1	34
44	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	7.2	31
45	Principles of Melanoma Staging. <i>Cancer Treatment and Research</i> , 2016, 167, 131-148.	0.0	29
46	Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.5	29
47	Sentinel Lymph Node Biopsy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 185-191.	2.0	28
48	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	13.0	27
49	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	7.2	26
50	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		26
51	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019, 15, e8323.	7.2	25
52	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	1.9	25
53	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.7	25
54	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3488-3497.	1.9	24

#	ARTICLE	IF	CITATIONS
55	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8001-8012.	7.5	21
56	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. Nature Communications, 2022, 13, 1859.	13.0	21
57	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 2022, 10, 996-1012.	3.3	21
58	Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nature Cancer, 2023, 4, 222-239.	12.1	21
59	Metastatic melanoma with spontaneous complete regression of a thick primary lesion. JAAD Case Reports, 2016, 2, 439-441.	0.9	18
60	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		18
61	Use of immunotherapy and surgery for stage IV melanoma. Cancer, 2020, 126, 2614-2624.	4.1	17
62	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports Medicine, 2022, 3, 100500.	5.9	17
63	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		16
64	Melanoma: Advances in Targeted Therapy and Molecular Markers. Annals of Surgical Oncology, 2015, 22, 3451-3458.	1.9	15
65	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-Resistant Melanoma. Genomics, Proteomics and Bioinformatics, 2020, 18, 26-40.	7.6	14
66	Low expression of the PPAR γ -regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases. Scientific Reports, 2021, 11, 7847.	3.4	14
67	Successful Mentor-Mentee Relationship. Journal of Surgical Research, 2020, 247, 332-334.	1.6	13
68	Surgical delay and mortality for primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2021, 84, 1089-1091.	1.2	13
69	Type 2 immunity is maintained during cancer-associated adipose tissue wasting. Immunotherapy Advances, 2021, 1, ltab011.	3.0	13
70	Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. Annals of Surgical Oncology, 2020, 27, 5128-5136.	1.9	13
71	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Frontiers in Oncology, 2020, 10, 757.	2.9	12
72	Prediction of early-stage melanoma recurrence using clinical and histopathologic features. Npj Precision Oncology, 2022, 6, .	5.4	12

#	ARTICLE	IF	CITATIONS
73	Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. <i>Nature Communications</i> , 2023, 14, .	13.0	12
74	Atypical ALK ⁺ positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 136-140.	1.4	11
75	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021, 26, e1427-e1433.	4.1	11
76	Oncolytic Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 419-430.	1.5	10
77	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		10
78	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.9	10
79	Tracking early response to immunotherapy. <i>Nature Cancer</i> , 2020, 1, 160-162.	12.1	9
80	Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. <i>Nature Immunology</i> , 2024, 25, 644-658.	13.7	9
81	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	1.9	8
82	The role of surgeons in building a personalized medicine program. <i>Journal of Surgical Oncology</i> , 2015, 111, 3-8.	1.7	7
83	PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin Plus Nivolumab in Resected Stage III/IV Melanoma at High Risk for Recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	2.4	7
84	Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	5
85	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1147-1149.	1.2	4
86	Incorporating Well-Being into Mentorship Meetings: A Case Demonstration at Massachusetts General Hospital Department of Surgery a Harvard Medical School Affiliate. <i>American Journal of Lifestyle Medicine</i> , 2023, 17, 213-215.	1.9	4
87	Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. <i>Journal of Clinical Oncology</i> , 2024, 42, 1169-1180.	5.4	4
88	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	4.1	3
89	Abstract 2030: A single-cell spatially resolved map of colorectal cancer identifies novel spatial relationships between cancer cells and the microenvironment. <i>Cancer Research</i> , 2022, 82, 2030-2030.	0.9	3
90	The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making. <i>Annals of Surgical Oncology</i> , 2019, 26, 2665-2666.	1.9	2

#	ARTICLE	IF	CITATIONS
91	920â€¦A single-cell spatially resolved MERFISH map of the colorectal tumor immune microenvironment. , 2021, , .		2
92	Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Clinical Cancer Research, 0, , OF1-OF16.	7.2	2
93	Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application. Journal of Investigative Dermatology, 2017, 137, 2466-2468.	0.7	1
94	Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors. Annals of Surgical Oncology, 2022, 29, 762-763.	1.9	1
95	Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma. Cancers, 2023, 15, 2700.	3.8	1
96	Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nature Reviews Cancer, 2024, 24, 498-512.	28.6	1
97	ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. Annals of Surgical Oncology, 2020, 27, 3498-3499.	1.9	0
98	ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era. Annals of Surgical Oncology, 2020, 27, 5137-5138.	1.9	0
99	641â€¦Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. , 2021, , .		0
100	MO344: Effect of Cancer Stage on Adverse Kidney Outcomes in Patients With Advanced Melanoma Treated With Immune Checkpoint Inhibitors. Nephrology Dialysis Transplantation, 2022, 37, .	0.8	0
101	Abstract 1270: Glycoproteomics-based liquid biopsy informs optimal checkpoint-inhibitor drug choice. Cancer Research, 2022, 82, 1270-1270.	0.9	0
102	Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Cancer Research, 2022, 82, 3610-3610.	0.9	0
103	ONCOS-102: A Step Forward or Sideways?. Clinical Cancer Research, 0, , OF1-OF2.	7.2	0
104	Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis. Annals of Surgical Oncology, 0, , .	1.9	0
105	Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma. JCO Precision Oncology, 2024, , .	3.1	0
106	Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. Nature Medicine, 2024, 30, 1349-1362.	29.9	0
107	Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial. Nature Communications, 2024, 15, .	13.0	0
108	Targeting IL-17A to combat immune-related adverse events. Nature Cancer, 0, , .	12.1	0

#	ARTICLE	IF	CITATIONS
109	Implementation and Evaluation of an Academic Development Rotation for Surgery Residents. Journal of Surgical Education, 2024, 81, 1748-1755.	2.5	0